DOCSLIB.ORG

Genetic Variation in Carboxylesterase Genes and Susceptibility to Isoniazid-Induced Hepatotoxicity

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Genetic Variation in Carboxylesterase Genes and Susceptibility to Isoniazid-Induced Hepatotoxicity The Pharmacogenomics Journal (2010) 10, 524–536 & 2010 Macmillan Publishers Limited. All rights reserved 1470-269X/10 www.nature.com/tpj ORIGINAL ARTICLE Genetic variation in carboxylesterase genes and susceptibility to isoniazid-induced hepatotoxicity S Yamada1,2, K Richardson3, Treatment of latent tuberculosis infection (LTBI) generally includes isoniazid 4 1 (INH), a drug that can cause serious hepatotoxicity. Carboxylesterases (CES) M Tang , J Halaschek-Wiener , are important in the metabolism of a variety of substrates, including 4,5 4 VJ Cook , JM FitzGerald , xenobiotics. We hypothesized that genetic variation in CES genes expressed K Elwood4, F Marra4,6,8 in the liver could affect INH-induced hepatotoxicity. Three CES genes are and A Brooks-Wilson1,7,8 known to be expressed in human liver: CES1, CES2 and CES4. Our aim was to systematically characterize genetic variation in these novel candidate genes 1Cancer Genetics, Canada’s Michael Smith and test whether it is associated with this adverse drug reaction. As part of a Genome Sciences Centre, British Columbia pilot study, 170 subjects with LTBI who received only INH were recruited, Cancer Agency, Vancouver, Canada; including 23 cases with hepatotoxicity and 147 controls. All exons and the 2Department of Life Science, Ritsumeikan University, Kusatsu Shiga, Japan; 3Centre for promoters of CES1, CES2 and CES4 were bidirectionally sequenced. A large Clinical Epidemiology and Evaluation, Vancouver polymorphic deletion was found to encompass exons 2 to 6 of CES4.No Coastal Health Research Institute, Vancouver, significant association was found. Eleven single-nucleotide polymorphisms 4 Canada; British Columbia Centre for Disease (SNPs) in CES1 were in high linkage disequilibrium with each other. One of Control, Vancouver, Canada; 5Faculty of Medicine, University of British Columbia, these SNPs, C(À2)G, alters the translation initiation sequence of CES1 and Vancouver, Canada; 6Department of Family represents a candidate functional polymorphism. Replication of this possible Practice, University of British Columbia, association in a larger sample set and functional studies will be necessary to 7 Vancouver, Canada and Department of determine if this CES1 variant has a role in INH-induced hepatotoxicity. Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, British Columbia, The Pharmacogenomics Journal (2010) 10, 524–536; doi:10.1038/tpj.2010.5; Canada published online 2 March 2010 Correspondence: Keywords: pharmacogenetics; tuberculosis; genetic association; single-nucleotide polymorph- Dr A Brooks-Wilson, Cancer Genetics, Canada’s ism; haplotype; case–control study Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, 675 W 10th Ave., Vancouver BC V5Z 4E6, Canada. E-mail: [email protected] Introduction Tuberculosis (TB) is a major global health problem. In Canada, groups at increased risk include Aboriginal persons, the foreign-born and inner city populations.1–3 Isoniazid (INH) is recommended as the drug of choice to treat latent tuberculosis infection (LTBI). Several adverse drug reactions (ADRs) are associated with INH, including hepatitis. A better understanding of the basis of this potentially life-threatening ADR is needed to inform preventive measures.4–6 The occurrence of ADRs related to INH, especially hepatotoxicity, has been well characterized.7 The incidence of INH-induced hepatotoxicity ranges from 1 to 36%, depending on different regimens, the population being treated and the definition of hepatic injury used.8,9 Alcohol consumption, presence of HIV, advanced age and chronic liver disease have been reported to increase the risk of INH-induced hepatotoxicity.10–14 8These authors co-led the study. N-acetyltransferase 2 (NAT2) is directly involved in INH metabolism, and genetic variation in the NAT2 gene has been reported to be a risk factor for INH- Received 23 August 2009; revised 22 November 2009; accepted 29 December 2009; published induced hepatotoxicity. There is wide variability in reported associations of NAT2 online 2 March 2010 variants with INH-induced hepatotoxicity in different populations;15–18 however, Genetic variation in CES genes and INH hepatotoxicity S Yamada et al 525 controversy remains regarding the importance of NAT2 ing exons of the three genes in all study subjects. This not variation for this ADR in different ethnic groups. Factors only addresses the effect of genetic variation in these genes that may contribute to heterogeneity of NAT2/hepatotoxi- on INH-induced hepatotoxicity in our population, but also city associations include genetic differences between popu- provides an extensive catalog of genetic variation to support lations17 and contributions of variation in other genes to other pharmacogenetic analyses of these genes. this ADR. It is likely that NAT2 variation accounts for only a portion of INH-induced hepatotoxicity.15–18 An amidase enzyme(s) catalyzes two steps in the metabo- Patients and methods lism of INH.19,20 There is strong evidence from an animal model that amidase activity levels influence hepatotoxicity; Study subjects rabbits treated with an amidase inhibitor, bis-p-nitrophenyl All individuals in British Columbia who are identified to phosphate, at the same time they are dosed with INH fail to have LTBI are eligible to receive preventative treatment develop the severe hepatotoxicity developed by animals through a publicly funded program. We enrolled subjects treated with INH alone.21 Modulation of hepatic amidase receiving treatment with INH (300 mg daily) for LTBI at the activity therefore affects the development of hepatotoxicity, Vancouver or Victoria TB Clinics from 2004 to 2006. likely by altering INH metabolism. By extension, naturally Inclusion criteria were as follows: subjects were included if occurring genetic variation in amidase genes may account they were 19 years of age or older, not receiving other anti- for at least some of the variation in susceptibility to INH- TB drugs concurrently with INH, nonreactive to hepatitis B induced hepatotoxicity. Given that INH metabolism occurs surface antigen and negative for antibody to hepatitis C by in the liver and that toxic metabolites released there are the serology, not having any liver or metabolic diseases, without cause of hepatotoxicity, amidase genes expressed in the liver an HIV þ test result, not consuming seven or more alcoholic are logical candidate genes for INH hepatotoxicity. Candi- beverages per day and had sufficient aspartate aminotrans- date genes for INH-induced hepatotoxicity were chosen ferase (AST) monitoring to detect an INH-induced hepato- based on three criteria: their ability to cleave amide bonds, toxicity event. their expression in the liver and their inhibition by bis-p- We selected serum AST at baseline and follow-up as a nitrophenyl phosphate. Cleavage of amide bonds is carried marker of hepatotoxicity. Although alanine transaminase is out by esterases, which can also cleave ester bonds. There are more specific for liver dysfunction, our local BC Centre for many esterases, but only a subset of them is inhibited by bis- Disease Control TB Clinic uses AST alone and considers a rise p-nitrophenyl phosphate, a selective inhibitor of ‘type B’ in AST after drug initiation without other confounders esterases, or cholinesterases and carboxylesterases (CES). (heart disease, muscle disease and so on) to be attributable to Cholinesterases (acetylcholinesterase and pseudocholines- medication. In addition, our research was conducted to terase) break down the neurotransmitter acetylcholine and, impact policy within our local TB Clinic and, as such, we as such, would not be expected to be involved in INH have conducted this study using measures that are consis- metabolism. tent with the Clinic’s policies and procedures. Three CES genes are well characterized in the human Information was collected regarding subject age, sex, genome: CES1, CES2 and CES3. All three are expressed in the ethnicity of each grandparent, concurrent medical illnesses liver. CES3 is more highly expressed in brain endothelial and alcohol and cigarette consumption. Confirmation of cells than in liver and has been suggested to function at the medication use, duration of treatment, all AST test dates and blood–brain barrier.22 CES1 (OMIM 114835) and CES2 results and hepatitis serology were obtained from the TB (OMIM 605278) are both highly expressed in the liver and Control database at the BC Centre for Disease Control. represent good candidates for genes involved in INH Baseline AST was measured before the initiation of INH metabolism. Both are located on human chromosome 16; treatment or as the first value entered into the subject’s CES1 has 14 exons and CES2 has 12.23 CES423 is a transcribed medical record within the first 2 weeks of treatment pseudogene located adjacent to and 28 kb upstream from initiation. Values were measured monthly thereafter until CES1. It has six transcribed exons and spans approximately treatment discontinuation or whenever subjects had symp- 14 kb.24 CES1 and CES4 have very high sequence similarity toms of suspected hepatitis (anorexia, nausea, vomiting, to each other; CES4 appears to be an inverted duplication of malaise and tea-colored urine). Serum hepatitis B virus CES1.25,26 Because of the proximity of CES1 and CES4 to surface antigen, immunoglobulin M antibody to hepatitis A each other and their similarity, we also characterized CES4 as virus and antibody to hepatitis C virus were tested at part
Load more

Recommended publications
  • Proteomic Analyses Reveal a Role of Cytoplasmic Droplets As an Energy Source During Sperm Epididymal Maturation
    Proteomic analyses reveal a role of cytoplasmic droplets as an energy source during sperm epididymal maturation Shuiqiao Yuana,b, Huili Zhenga, Zhihong Zhengb, Wei Yana,1 aDepartment of Physiology and Cell Biology, University of Nevada School of Medicine, Reno, NV, 89557; and bDepartment of Laboratory Animal Medicine, China Medical University, Shenyang, 110001, China Corresponding author. Email: [email protected] Supplemental Information contains one Figure (Figure S1), three Tables (Tables S1-S3) and two Videos (Videos S1 and S2) files. Figure S1. Scanning electron microscopic images of purified murine cytoplasmic droplets. Arrows point to indentations resembling the resealed defects at the detaching points when CDs come off the sperm flagella. Scale bar = 1µm Table S1 Mass spectrometry-based identifiaction of proteins highly enriched in murine cytoplasmic droplets. # MS/MS View:Identified Proteins (105) Accession Number Molecular Weight Protein Grouping Ambiguity Dot_1_1 Dot_2_1 Dot_3_1 Dot_4_1Dot_5_1 Dot_1_2 Dot_2_2 Dot_3_2 Dot_4_2 Dot_5_2 1 IPI:IPI00467457.3 Tax_Id=10090 Gene_Symbol=Ldhc L-lactate dehydrogenase C chain IPI00467457 36 kDa TRUE 91% 100% 100% 100% 100% 100% 100% 100% 100% 2 IPI:IPI00473320.2 Tax_Id=10090 Gene_Symbol=Actb Putative uncharacterized protein IPI00473320 42 kDa TRUE 75% 100% 100% 100% 100% 89% 76% 100% 100% 100% 3 IPI:IPI00224181.7 Tax_Id=10090 Gene_Symbol=Akr1b7 Aldose reductase-related protein 1 IPI00224181 36 kDa TRUE 100% 100% 76% 100% 100% 4 IPI:IPI00228633.7 Tax_Id=10090 Gene_Symbol=Gpi1 Glucose-6-phosphate
    [Show full text]
  • 1 Metabolic Dysfunction Is Restricted to the Sciatic Nerve in Experimental
    Page 1 of 255 Diabetes Metabolic dysfunction is restricted to the sciatic nerve in experimental diabetic neuropathy Oliver J. Freeman1,2, Richard D. Unwin2,3, Andrew W. Dowsey2,3, Paul Begley2,3, Sumia Ali1, Katherine A. Hollywood2,3, Nitin Rustogi2,3, Rasmus S. Petersen1, Warwick B. Dunn2,3†, Garth J.S. Cooper2,3,4,5* & Natalie J. Gardiner1* 1 Faculty of Life Sciences, University of Manchester, UK 2 Centre for Advanced Discovery and Experimental Therapeutics (CADET), Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, UK 3 Centre for Endocrinology and Diabetes, Institute of Human Development, Faculty of Medical and Human Sciences, University of Manchester, UK 4 School of Biological Sciences, University of Auckland, New Zealand 5 Department of Pharmacology, Medical Sciences Division, University of Oxford, UK † Present address: School of Biosciences, University of Birmingham, UK *Joint corresponding authors: Natalie J. Gardiner and Garth J.S. Cooper Email: [email protected]; [email protected] Address: University of Manchester, AV Hill Building, Oxford Road, Manchester, M13 9PT, United Kingdom Telephone: +44 161 275 5768; +44 161 701 0240 Word count: 4,490 Number of tables: 1, Number of figures: 6 Running title: Metabolic dysfunction in diabetic neuropathy 1 Diabetes Publish Ahead of Print, published online October 15, 2015 Diabetes Page 2 of 255 Abstract High glucose levels in the peripheral nervous system (PNS) have been implicated in the pathogenesis of diabetic neuropathy (DN). However our understanding of the molecular mechanisms which cause the marked distal pathology is incomplete. Here we performed a comprehensive, system-wide analysis of the PNS of a rodent model of DN.
    [Show full text]
  • Toxicogenomics Applications of New Functional Genomics Technologies in Toxicology
    \-\w j Toxicogenomics Applications of new functional genomics technologies in toxicology Wilbert H.M. Heijne Proefschrift ter verkrijging vand egraa dva n doctor opgeza gva nd e rector magnificus vanWageninge n Universiteit, Prof.dr.ir. L. Speelman, in netopenbaa r te verdedigen op maandag6 decembe r200 4 des namiddagst e half twee ind eAul a - Table of contents Abstract Chapter I. page 1 General introduction [1] Chapter II page 21 Toxicogenomics of bromobenzene hepatotoxicity: a combined transcriptomics and proteomics approach[2] Chapter III page 48 Bromobenzene-induced hepatotoxicity atth etranscriptom e level PI Chapter IV page 67 Profiles of metabolites and gene expression in rats with chemically induced hepatic necrosis[4] Chapter V page 88 Liver gene expression profiles in relation to subacute toxicity in rats exposed to benzene[5] Chapter VI page 115 Toxicogenomics analysis of liver gene expression in relation to subacute toxicity in rats exposed totrichloroethylen e [6] Chapter VII page 135 Toxicogenomics analysis ofjoin t effects of benzene and trichloroethylene mixtures in rats m Chapter VII page 159 Discussion and conclusions References page 171 Appendices page 187 Samenvatting page 199 Dankwoord About the author Glossary Abbreviations List of genes Chapter I General introduction Parts of this introduction were publishedin : Molecular Biology in Medicinal Chemistry, Heijne etal., 2003 m NATO Advanced Research Workshop proceedings, Heijne eral., 2003 81 Chapter I 1. General introduction 1.1 Background /.1.1 Toxicologicalrisk
    [Show full text]
  • Carboxylesterase 1 / CES1 Antibody (Internal) Goat Polyclonal Antibody Catalog # ALS12250
    10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 Carboxylesterase 1 / CES1 Antibody (Internal) Goat Polyclonal Antibody Catalog # ALS12250 Specification Carboxylesterase 1 / CES1 Antibody (Internal) - Product Information Application WB, IHC Primary Accession P23141 Reactivity Human Host Goat Clonality Polyclonal Calculated MW 63kDa KDa Carboxylesterase 1 / CES1 Antibody (Internal) - Additional Information Gene ID 1066 Antibody (0.03 ug/ml) staining of Human Liver lysate (35 ug protein in RIPA buffer). Other Names Liver carboxylesterase 1, Acyl-coenzyme A:cholesterol acyltransferase, ACAT, Brain carboxylesterase hBr1, Carboxylesterase 1, CE-1, hCE-1, 3.1.1.1, Cocaine carboxylesterase, Egasyn, HMSE, Methylumbelliferyl-acetate deacetylase 1, 3.1.1.56, Monocyte/macrophage serine esterase, Retinyl ester hydrolase, REH, Serine esterase 1, Triacylglycerol hydrolase, TGH, CES1, CES2, SES1 Target/Specificity Human CES1. This antibody is expected to recognise all three reported isoforms (NP_001020366.1; NP_001020365.1; Anti-CES1 antibody IHC of human lung. NP_001257.4). Reconstitution & Storage Carboxylesterase 1 / CES1 Antibody Store at -20°C. Minimize freezing and (Internal) - Background thawing. Involved in the detoxification of xenobiotics Precautions and in the activation of ester and amide Carboxylesterase 1 / CES1 Antibody prodrugs. Hydrolyzes aromatic and aliphatic (Internal) is for research use only and not esters, but has no catalytic activity toward for use in diagnostic or therapeutic amides or a fatty acyl-CoA ester. Hydrolyzes procedures. the methyl ester group of cocaine to form benzoylecgonine. Catalyzes the transesterification of cocaine to form Carboxylesterase 1 / CES1 Antibody (Internal) - cocaethylene. Displays fatty acid ethyl ester Protein Information synthase activity, catalyzing the ethyl esterification of oleic acid to ethyloleate.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Current Drug Metabolism, 2019, 20, 91-102
    Send Orders for Reprints to [email protected] 91 Current Drug Metabolism, 2019, 20, 91-102 REVIEW ARTICLE ISSN: 1389-2002 eISSN: 1875-5453 Current Drug Impact Factor: Metabolism 2.655 The Impact of Carboxylesterases in Drug Metabolism and Pharmacokinetics The international journal for timely in-depth reviews on Drug Metabolism BENTHAM SCIENCE Li Di* Pfizer Inc., Eastern Point Road, Groton, Connecticut, CT 06354, USA Abstract: Background: Carboxylesterases (CES) play a critical role in catalyzing hydrolysis of esters, amides, car- bamates and thioesters, as well as bioconverting prodrugs and soft drugs. The unique tissue distribution of CES en- zymes provides great opportunities to design prodrugs or soft drugs for tissue targeting. Marked species differences in CES tissue distribution and catalytic activity are particularly challenging in human translation. Methods: Review and summarization of CES fundamentals and applications in drug discovery and development. A R T I C L E H I S T O R Y Results: Human CES1 is one of the most highly expressed drug metabolizing enzymes in the liver, while human intestine only expresses CES2. CES enzymes have moderate to high inter-individual variability and exhibit low to no expression in the fetus, but increase substantially during the first few months of life. The CES genes are highly po- Received: June 04, 2018 Revised: August 03, 2018 lymorphic and some CES genetic variants show significant influence on metabolism and clinical outcome of certain Accepted: August 08, 2018 drugs. Monkeys appear to be more predictive of human pharmacokinetics for CES substrates than other species. Low risk of clinical drug-drug interaction is anticipated for CES, although they should not be overlooked, particularly DOI: 10.2174/1389200219666180821094502 interaction with alcohols.
    [Show full text]
  • The Metabolic Serine Hydrolases and Their Functions in Mammalian Physiology and Disease Jonathan Z
    REVIEW pubs.acs.org/CR The Metabolic Serine Hydrolases and Their Functions in Mammalian Physiology and Disease Jonathan Z. Long* and Benjamin F. Cravatt* The Skaggs Institute for Chemical Biology and Department of Chemical Physiology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States CONTENTS 2.4. Other Phospholipases 6034 1. Introduction 6023 2.4.1. LIPG (Endothelial Lipase) 6034 2. Small-Molecule Hydrolases 6023 2.4.2. PLA1A (Phosphatidylserine-Specific 2.1. Intracellular Neutral Lipases 6023 PLA1) 6035 2.1.1. LIPE (Hormone-Sensitive Lipase) 6024 2.4.3. LIPH and LIPI (Phosphatidic Acid-Specific 2.1.2. PNPLA2 (Adipose Triglyceride Lipase) 6024 PLA1R and β) 6035 2.1.3. MGLL (Monoacylglycerol Lipase) 6025 2.4.4. PLB1 (Phospholipase B) 6035 2.1.4. DAGLA and DAGLB (Diacylglycerol Lipase 2.4.5. DDHD1 and DDHD2 (DDHD Domain R and β) 6026 Containing 1 and 2) 6035 2.1.5. CES3 (Carboxylesterase 3) 6026 2.4.6. ABHD4 (Alpha/Beta Hydrolase Domain 2.1.6. AADACL1 (Arylacetamide Deacetylase-like 1) 6026 Containing 4) 6036 2.1.7. ABHD6 (Alpha/Beta Hydrolase Domain 2.5. Small-Molecule Amidases 6036 Containing 6) 6027 2.5.1. FAAH and FAAH2 (Fatty Acid Amide 2.1.8. ABHD12 (Alpha/Beta Hydrolase Domain Hydrolase and FAAH2) 6036 Containing 12) 6027 2.5.2. AFMID (Arylformamidase) 6037 2.2. Extracellular Neutral Lipases 6027 2.6. Acyl-CoA Hydrolases 6037 2.2.1. PNLIP (Pancreatic Lipase) 6028 2.6.1. FASN (Fatty Acid Synthase) 6037 2.2.2. PNLIPRP1 and PNLIPR2 (Pancreatic 2.6.2.
    [Show full text]
  • Baboon JMP CES Paper
    Baboon carboxylesterases 1 and 2: sequences, structures and phylogenetic relationships with human and other primate carboxylesterases Author Holmes, Roger S, Glenn, Jeremy P, VandeBerg, John L, Cox, Laura A Published 2009 Journal Title Journal of Medical Primatology DOI https://doi.org/10.1111/j.1600-0684.2008.00315.x Copyright Statement © 2009 John Wiley & Sons A/S. This is the author-manuscript version of the paper. Reproduced in accordance with the copyright policy of the publisher.The definitive version is available at www.interscience.wiley.com Downloaded from http://hdl.handle.net/10072/29362 Griffith Research Online https://research-repository.griffith.edu.au Baboon Carboxylesterases 1 and 2: Sequences, Structures and Phylogenetic Relationships with Human and other Primate Carboxylesterases Roger S. Holmes 1,2,3 , Jeremy P. Glenn 1, John L. VandeBerg 1,2 , Laura A. Cox 1,2,4 1. Department of Genetics and 2. Southwest National Primate Research Center, Southwest Foundation for Biomedical Research, San Antonio, TX, USA, and 3. School of Biomolecular and Physical Sciences, Griffith University, Nathan. Queensland, Australia 4. Corresponding Author: Laura A. Cox, Ph.D. Department of Genetics Southwest National Primate Research Center Southwest Foundation for Biomedical Research San Antonio, TX, USA 78227 Email: [email protected] Phone: 210-258-9687 Fax: 210-258-9600 Keywords: cDNA sequence; amino acid sequence; 3-D structure Running Head: Carboxylesterases: sequences and phylogeny Published in Journal of Medical Primatology (2009) 38: 27-38. Abstract Background Carboxylesterase (CES) is predominantly responsible for the detoxification of a wide range of drugs and narcotics, and catalyze several reactions in cholesterol and fatty acid metabolism.
    [Show full text]
  • NIH Public Access Author Manuscript Mamm Genome
    NIH Public Access Author Manuscript Mamm Genome. Author manuscript; available in PMC 2011 October 8. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Mamm Genome. 2010 October ; 21(9-10): 427±441. doi:10.1007/s00335-010-9284-4. Recommended nomenclature for five mammalian carboxylesterase gene families: human, mouse, and rat genes and proteins Roger S. Holmes Department of Genetics, Southwest Foundation for Biomedical Research, San Antonio, TX 78227-5301, USA Southwest National Primate Research Center, Southwest Foundation for Biomedical Research, San Antonio, TX, USA School of Biomolecular and Physical Sciences, Griffith University, Brisbane, QLD, Australia Matthew W. Wright European Bioinformatics Institute, Wellcome Trust Genome Campus, Cambridge, UK Stanley J. F. Laulederkind Rat Genome Database, Human Molecular Genetics Center, Medical College of Wisconsin, Milwaukee, WI, USA Laura A. Cox Department of Genetics, Southwest Foundation for Biomedical Research, San Antonio, TX 78227-5301, USA Southwest National Primate Research Center, Southwest Foundation for Biomedical Research, San Antonio, TX, USA Masakiyo Hosokawa Laboratory of Drug Metabolism and Biopharmaceutics, Chiba Institute of Science, Choshi, Chiba, Japan Teruko Imai Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan Shun Ishibashi Department of Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan Richard Lehner CIHR Group on Molecular and Cell Biology of Lipids, University of Alberta, Edmonton, AB, Canada Masao Miyazaki The Institute of Glycoscience, Tokai University, Kanagawa, Japan Everett J. Perkins Department of Drug Disposition, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA Phillip M. Potter © Springer Science+Business Media, LLC 2010 [email protected] . Holmes et al.
    [Show full text]
  • Synthesis, Molecular Docking, and Biological Evaluation of 3-Oxo-2
    Bioorganic Chemistry 91 (2019) 103097 Contents lists available at ScienceDirect Bioorganic Chemistry journal homepage: www.elsevier.com/locate/bioorg Synthesis, molecular docking, and biological evaluation of 3-oxo-2- T tolylhydrazinylidene-4,4,4-trifluorobutanoates bearing higher and natural alcohol moieties as new selective carboxylesterase inhibitors Galina F. Makhaevaa, Natalia A. Elkinab, Evgeny V. Shchegolkovb, Natalia P. Boltnevaa, Sofya V. Lushchekinac, Olga G. Serebryakovaa, Elena V. Rudakovaa, Nadezhda V. Kovalevaa, Eugene V. Radchenkod, Vladimir A. Palyulind, Yanina V. Burgartb, Victor I. Saloutinb, ⁎ Sergey O. Bachurina, Rudy J. Richardsone,f, a Institute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka 142432, Russia b Postovsky Institute of Organic Synthesis, Urals Branch of Russian Academy of Sciences, Yekaterinburg 620990, Russia c Emanuel Institute of Biochemical Physics Russian Academy of Sciences, Moscow 119334, Russia d Department of Chemistry, Lomonosov Moscow State University, Moscow 119991, Russia e Departments of Environmental Health Sciences and Neurology, University of Michigan, Ann Arbor, MI 48109, USA f Center for Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI 48109, USA ARTICLE INFO ABSTRACT Keywords: To search for effective and selective inhibitors of carboxylesterase (CES), a series of 3-oxo-2-tolylhy- 3-oxo-2-tolylhydrazinylidene-4,4,4- drazinylidene-4,4,4-trifluorobutanoates bearing higher or natural alcohol moieties was synthesized viapre- trifluorobutanoates transesterification of ethyl trifluoroacetylacetate with alcohols to isolate transesterificated oxoesters aslithium Higher alcohols salts, which were then subjected to azo coupling with tolyldiazonium chloride. Inhibitory activity against por- Natural alcohols cine liver CES, along with two structurally related serine hydrolases, acetylcholinesterase and butyr- Transesterification ylcholinesterase, were investigated using enzyme kinetics and molecular docking.
    [Show full text]
  • Recombinant Human Carboxylesterase 1/CES1 Protein Catalog Number: ATGP3862
    Recombinant human Carboxylesterase 1/CES1 protein Catalog Number: ATGP3862 PRODUCT INPORMATION Expression system Baculovirus Domain 19-568aa UniProt No. P23141 NCBI Accession No. NP_001020366 Alternative Names Liver carboxylesterase 1 isoform a, CES1, ACAT, CE-1, CEH, CES2, hCE-1, HMSE, HMSE1, PCE-1, REH, SES1, TGH PRODUCT SPECIFICATION Molecular Weight 61.7 kDa (559aa) Concentration 0.5mg/ml (determined by absorbance at 280nm) Formulation Liquid in. 25mM Sodium Acetate (pH 4.0) containing 10% glycerol, 0.1M NaCl, 0.1mM PMSF Purity > 90% by SDS-PAGE Endotoxin level < 1 EU per 1ug of protein (determined by LAL method) Biological Activity Specific activity is > 700pmol/min/ug and is defined as the amount of enzyme that hydrolyze 1pmole of p- nitrophenyl acetate to pnitrophenol per minute at pH 7.5 at 37C. Tag His-Tag Application Enzyme Activity,SDS-PAGE Storage Condition Can be stored at +2C to +8C for 1 week. For long term storage, aliquot and store at -20C to -80C. Avoid repeated freezing and thawing cycles. BACKGROUND 1 Recombinant human Carboxylesterase 1/CES1 protein Catalog Number: ATGP3862 Description Carboxylesterase 1, also known as liver carboxylesterase 1 isoform a, is a member of a large family of carboxylesterases. It is also part of the alpha/beta fold hydrolase family. Carboxylesterases hydrolyze long-chain fatty acid esters and thioesters. The resulting carboxylates are then often conjugated by other enzymes to increase solubility and eventually excreted. Also, this enzyme may play a role in detoxification in the lung and/or protection of the central nervous system from ester or amide compounds.
    [Show full text]
  • Carboxylesterases in Lipid Metabolism: from Mouse to Human
    Protein Cell DOI 10.1007/s13238-017-0437-z Protein & Cell REVIEW Carboxylesterases in lipid metabolism: from mouse to human & Jihong Lian1,2 , Randal Nelson1,2, Richard Lehner1,2,3 1 Group on Molecular and Cell Biology of Lipids, University of Alberta, Edmonton, Alberta, Canada 2 Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada 3 Department of Cell Biology, University of Alberta, Edmonton, Alberta, Canada & Correspondence: [email protected] (J. Lian) Received March 2, 2017 Accepted May 31, 2017 Cell & ABSTRACT Hatfield et al., 2016; Fukami et al., 2015; Laizure et al., 2013; Staudinger et al., 2010; Sanghani et al., 2009; Imai, 2006). Mammalian carboxylesterases hydrolyze a wide range However, carboxylesterases have also been demonstrated of xenobiotic and endogenous compounds, including to hydrolyze endogenous esters and thioesters including lipid esters. Physiological functions of car- lipids and some of these enzymes have been shown to play Protein boxylesterases in lipid metabolism and energy home- important physiological functions in lipid metabolism and ostasis in vivo have been demonstrated by genetic energy homeostasis. Recent research endeavors have manipulations and chemical inhibition in mice, and provided more insight into the roles of human car- in vitro through (over)expression, knockdown of boxylesterases in metabolic diseases. expression, and chemical inhibition in a variety of cells. Genes encoding six human carboxylesterases and twenty Recent research advances have revealed the relevance mouse carboxylesterases have been classified. However, of carboxylesterases to metabolic diseases such as given the interspecies diversity of carboxylesterases both in obesity and fatty liver disease, suggesting these the number and primary amino acid sequences there is a enzymes might be potential targets for treatment of need to define functional mouse and human orthologs.
    [Show full text]